CEO Malcolm McColl speaks at Bell Potter Healthcare Conference

ImmVirX is pleased to advise that Co-Founder and CEO Dr Malcolm McColl’s presentation at the Bell Potter Healthcare Conference 2023 held in November is available to view here.

Join Our Mailing List

Our mission is to develop receptor targeted, oncolytic RNA immunotherapies to provide durable responses and high quality of life in patients with some of the most globally prevalent cancers

About Us
Our Technology
Immvirx logo

A clinical stage company developing receptor targeted oncolytic RNA immunotherapies to enable powerful and durable responses in the most globally prevalent cancers with high unmet need.

Twitter Linkedin
Company
© 2024 ImmVirX Pty Ltd • Site by Noise